E. David Crawford, MD: Options to Control Recurrent Metastatic Disease
Watch
Judd W. Moul, MD, FACS: Chemotherapy Consideration
Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease
Metastatic Prostate Cancer: Case 1
Metastatic Prostate Cancer
Pierre Gholam, MD: Treatment Selection
Pierre Gholam, MD: Alcohol Abuse Impact on Treatment
Nicholas Nissen, MD: Treatment Selection
Nicholas Nissen, MD: Monitoring of Patient
Richard Finn, MD: Treatment Selection
Richard Finn, MD: Most Appropriate Treatment
Unresectable Hepatocellular Carcinoma: case 3
Unresectable Hepatocellular Carcinoma
Pierre Gholam, MD: Potential for Systemic Therapy
Pierre Gholam, MD: Recommended Screening
Nicholas Nissen, MD: Potential for Systemic Therapy
Nicholas Nissen, MD: Estimate of TACE Procedures
Richard Finn, MD: Potential for Systemic Therapy
Richard Finn, MD: Significance of Baseline AFP Levels
Unresectable Hepatocellular Carcinoma: case 2
Pierre Gholam, MD: Consideration of Different Modalities
Pierre Gholam, MD: Next Steps for Jose
Nicholas Nissen, MD: Next Steps for Jose
Nicholas Nissen, MD: Consideration of Different Modalities
Richard Finn, MD: Next Steps for Jose
Richard Finn, MD: Consideration of Different Modalities
Unresectable Hepatocellular Carcinoma: case 1
Denise A Yardley MD: Controlling Metastatic Disease
Denise A. Yardley, MD: Taxane Resistance
Denise A. Yardley, MD: Triple-Negative Phenotype's Influence on Treatment
William J. Gradishar, MD: Triple-Negative Phenotype's Influence on Treatment
William J. Gradishar, MD: Taxane Resistance
